“The addition of transplant to novel agent triplet induction therapy using lenalidomide, bortezomib, and dexamethasone [RVd] followed by lenalidomide maintenance until disease progression resulted in a highly significant increase in progression-free survival, with an improvement in the median of over 21 months.
← all excerpts
Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner.
1
—
—